Article Text

Download PDFPDF

Lung cancer investigation, treatment and survival
P95 Assessment of F/HN-pseudotyped Lentivirus as a Clinically Relevant Vector For Lung Gene Therapy
  1. U Griesenbach1,
  2. M Inoue2,
  3. C Meng1,
  4. R Farley1,
  5. M Chan1,
  6. NK Newman1,
  7. A Brum1,
  8. J You2,
  9. A Kerton3,
  10. A Shoemark4,
  11. AC Boyd5,
  12. JC Davies1,
  13. TE Higgins1,
  14. DR Gill6,
  15. SC Hyde6,
  16. JA Innes5,
  17. DJ Porteous5,
  18. M Hasegawa2,
  19. EWFW Alton1
  1. 1Department of Gene Therapy, Imperial College London, London, UK
  2. 2DNAVEC Corporation, Tsukuba, Japan
  3. 3Central Biomedical Services, Imperial College London, London, UK
  4. 4Paediatric Department, Royal Brompton Hospital, London, UK
  5. 5Medical Genetics Section, Centre for Molecular Medicine, MRC Institute of Genetics and Molecular Medicine University of Edinburgh, Western General Hospital, Edinburgh, UK
  6. 6Gene Medicine Group, Nuffield Dept of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK


Rational Our ongoing efforts to improve pulmonary gene transfer thereby enabling gene therapy for the treatment of lung diseases such as cystic fibrosis (CF) has led to the development of a lentiviral vector (SIV) pseudotyped with the Sendai virus envelope proteins F and HN.

Objectives Here, we begin to place this vector onto a translational pathway to the clinic, by addressing some key milestones that have to be achieved.

Main results These include: (1) a single dose produces lung expression for the life-time of the mouse (approximately 2 years), (2) only brief contact time is needed to achieve transduction, (3) repeated daily administration leads to a dose-related increase in gene expression, (4) repeated monthly administration to mouse lower airways is feasible without loss of gene expression, (5) there is no evidence of chronic toxicity during a 2 year study period, (6) F/HN-SIV transduction generates persistent gene expression in human differentiated airway cultures, and human lung slices and transduces freshly obtained primary human airway epithelial cells.

Conclusions The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene therapy for a number of diseases including CF and we are now undertaking the necessary refinements to progress this vector into clinical trials.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.